Systemic antibiotics for treating diabetic foot infections

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Selva Olid, Anna ^a   Solà, Ivan ^b   Barajas Nava, Leticia A ^c   Gianneo, Oscar D ^d   Bonfill Cosp, Xavier ^b   Lipsky, Benjamin A ^e,f,g  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d Centro Colaborador Cochrane   (Uruguay)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFOXITIN; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINAFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DAPTOMYCIN; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

DIABETES MELLITUS; DIABETIC FOOT; DIABETIC FOOT INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOOT CARE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LENGTH OF STAY; LIVER TOXICITY; MORTALITY; NAUSEA; NEPHROTOXICITY; OSTEOMYELITIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING; WOUND HEALING; BACTERIAL INFECTIONS; META ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; CEPHALOSPORINS; DIABETIC FOOT; FLUOROQUINOLONES; HUMANS; PENICILLINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945265455     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009061.pub2     Document Type: Review

References (107)

1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clinical Infectious Diseases 2004;38:1673-81.
2. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 2005;55:240-5.
3. Bouter KP, Visseren FL, Loenhout RM, Bartelink AK, Erkelens DW, Diepersloot RJ. Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy. International Journal of Antimicrobial Agents 1996;7:143-7.
4. Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity Infections in older males. The American Journal of Geriatric Pharmacotherapy 2004;2(3):181-9.
5. Erstad BL, McIntyre KE. Prospective, randomized comparison of ampicillin/sulbactam and cefoxitin for diabetic foot infections. Vascular Surgery 1997;31(4):419-26.
6. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous pipreacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents 2005;26:357-65.
7. Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Disease 2002;34:1460-8.
8. Graham DR, Talan DA, Nichols RL, Lucasti C, Corrado M, Morgan N, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clinical Infectious Diseases 2002;35:381-9.
9. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clinical Infectious Disease 1994;18:683-93.
10. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness ofaAmpicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clinical Infectious Disease 1997;24:57-63.
11. Harkless L, Boghossian J, Pollak R, Caputo W, Dona A, Gray S, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surgical Infections 2005;6:27-40.
12. Lauf L, Ozsvár Z, Mitha I, Regöly-Mérei J, Embil JM, Cooper A, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagnostic Microbiology and Infectious Disease 2014;78:469-80.
13. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JE. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Archives of Internal Medicine 1990;150:790-7.
14. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clinical Infectious Diseases 1997;24:643-8.
15. Lipsky BA, Itani K, Norden C and the Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clinical Infectious Disease 2004;38:17-34.
16. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clinical Infectious Diseases 2008;46:647-55.
17. Gynssens IC, Dryden M, Kujath P, Nathwani D, Schaper N, Hampel B, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2011;66:2632-42.
18. Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, et al. Efficacy of moxifloxacin in the treatment of diabetic foot infections: results of the RELIEF study. Diabetologia 2010;53 Suppl1:462-3.
19. Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Infectious Diseases 2010;16:1252-7.
20. Siami G, Christou N, Eiseman I, Tack KJ and the Clinafloxacin Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2001;45(2):525-31.
21. Abramson MA. The SIDESTEP study of diabetic foot infections (DFI): a multicenter, double-blinded, randomized, controlled trial (RCT) of ertapenem (E)v s. piperacillin/tazobactam (P/T). Diabetologia. 2005; Vol. 48 Suppl 1:A81-2.
22. Lipsky BA, Armstrong D, Citron D, Halperin GJ, Sheehan P, Tice A, et al. The SIDESTEP study of diabetic foot infections (DFI): a multicenter, double-blinded, randomized, controlled trial (RCT) of ertapenem (E) vs. piperacillin/tazobactam (P/T). Society of Hospital Medicine. 2005 Annual Meeting Abstracts:28.
23. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005;366:1695-703.
24. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009;37(5):407-17.
25. Tan JS, Wishnow M, Talan DA, Duncanson FP, Norden CW and the Piperacillin/Tazobactam Skin And Skin Strucutre Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrobial Agents and Chemotherapy 1993;37(8):1580-6.
26. Acevedo A, Schoop W, Shnell A, Toledo L. Antibiotic treatment for diabetic foot. Advantages of intravenous regional route as alternative for systemic route [Tratamiento antibiótico del pie diabético. Ventajas de la vía regional intravenosa como alternativa a la vía sistémica]. Revista Médica de Chile 1990;118(8):881-8.
27. Akova M, Ozcebe O, Gullu I, Unal S, Gur D, Akalin S, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. Journal of Chemotherapy (Florence, Italy) 1996;8:284-9.
28. Al-Ebous AD, Hiasat B, Sarayrah M, Al-Jahmi M, Al-Zuriqat AN. Management of diabetic foot in a Jordanian hospital. La Revue de Santé de la Méditerranée Orientale 2005;11(3):490-3.
29. Beam TR Jr, Gutierrez I, Powell S, Hewitt R, Hocko M, Brackett M, et al. Prospective study of the efficacy and safety or oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Reviews of Infectious Diseases 1989;11 Suppl 5:1163.
30. Bradsher RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. The American Journal of Medicine 1984;19:63-7.
31. Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2007;51(7):2628-30.
32. Chantelau E, Tanudjaja T, Altenhöfer F, Ersanli Z, Lacigova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabetic Medicine 1996;13:156-9.
33. Chen F, Zheng N, Wang Y, Wen JL, Tu WF, Du YQ, et al. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: A meta-analysis of randomised controlled trials. International Journal of Clinical Practice 2013;67:934-42.
34. Crouzet J, Lavigne JP, Richard JL, Sotto A, Nimes University Hospital Working Group on the Diabetic Foot (GP30). Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. International Journal of Infectious Diseases 2011;15:601-10.
35. Daniel R, and the Trovafloxacin Study Group. Comparison of the efficacy and safety of once-daily oral trovafloxacin and 3-times-daily amoxicillin/clavulanic acid for the treatment of complicated skin and soft-tissue infections. Drugs 1999;58 Suppl 2:288-90.
36. Darwish AA, Reddy A, Kamal M, Yaneza A, Al-Teheawy MM. Management of diabetic foot lesions with limited use of antibiotics. Annals of Saudi Medicine 1993;13(1):101-3.
37. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagnostic Microbiology and Infectious Disease 2008;61:103-9.
38. Edmonds M, Foster A. The use of antibiotics in the diabetic foot. American Journal of Surgery 2004;187 Suppl 5A:25-8.
39. Embil JM, Soto NE, Melnick DA. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Clinical Therapeutics 2006;28(8):1164-74.
40. Fernández JI, McCook J, Lima B, Velasco N, Montalvo J, Mahía M. Antibiotic treatment in patients amputated for ischemic diabetic foot [Antibioticoterapia en pacientes amputados por pie diabético isquémico]. Angiologia 1991;43(5):200-3.
41. File TM, Tan JS. Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). The American Journal of Medicine 1983;29:100-5.
42. File TM, Tan JS. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. European Journal of Surgery 1994;Suppl 573:51-5.
43. Foster A, McColgan M, Edmonds M. Should oral antibiotics be given to "clean" foot ulcers with no cellulitis?. Diabetic Medicine 1998;15 Suppl 2:10.
44. Gentry L, Ramírez-Ronda CH, Rodríguez-Noriega E, Thadepalli H, Leal del Rosal P, Ramirez C. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Archives of Internal Medicine 1989;149:2579-83.
45. Gentry LO, Rodriguez-Gomez G, ZeluffBJ, Khoshdel A, Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. The American Journal of Medicine 1989;87 Suppl 6C:57-60.
46. Hughes CE, Johnson CC, Bamberger DM, Reinhardt JF, Peterson LR, Mulligan ME, et al. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clinical Therapeutics 1987;10 Suppl A:36-49.
47. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin resistant Staphylococcus aureus. American Journal of Surgery 2010;199:804-16.
48. Joshi S, Maroli S, Moulick ND, Badhane S, Joshi S, Sthalekar N, et al. Efficacy and tolerability of a combination of ofloxacin and tinidazole in the management of infectious diabetic foot ulcer. Journal of the Indian Medical Association 2003;101:329-32.
49. Lipsky BA, Itani KM, Weigelt JA, Joseph W, Paap CM, Reisman A, et al. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. International Journal of Infectious Diseases 2011;15:140-6.
50. Lipsky BA, Miller B, Schwartz R, Henry DC, Nolan T, McCabe A, et al. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. Clinical Therapeutics 1999;21(4):675-90.
51. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabetic Medicine 2006;23(4):348-59.
52. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 2008;52(1):37-44.
53. Pérez-Ruvalcaba JA, Quintero-Pérez NP, Morales-Reyes JJ, Huitrón-Ramírez JA, Rodríguez-Chagollán JJ, Rodríguez-Noriega E. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. The American Journal of Medicine 1987;82 Suppl 4A:242-6.
54. Peters EJG, Lipsky BA, Berendt AR, Embil JM, Lavery LA, Senneville E, et al. A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:142-62.
55. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding D. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. The American Journal of Medicine 1989;86:801-8.
56. Siami FS, LaFleur BJ, Siami GA. Cinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a veterans affairs medical center. Clinical Therapeutics 2002;24:59-72.
57. Siebert T, Evans P. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections. The American Journal of Medicine 1985;79 Suppl 5B:141-5.
58. Smith OB, Richards CS, Taylor AT, Nesbit RR, Fisher JF, Willis EB. Prospective, controlled, randomized, evaluator-blind, comparative study of oral ciprofloxacin with and without oral metronidazole versus intravenous ticarcillin/clavulanic acid followed by oral amoxicillin/clavulanic acid in the treatment of diabetic foot infections. ASHP Midyear Clinical Meeting 1992;27:P-159R.
59. Smith JW, Nichols RL. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. The American Journal of Medicine 1993;94 Suppl 3A:150-3.
60. Stevens DL. Teicoplanin for skin and soft tissue infections: an open study and a randomized, comparative trial versus cefazolin. Journal of Infection and Chemotherapy 1999;5:40-5.
61. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2000;44(12):3408-13.
62. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 2002;34:1481-90.
63. Stupin VA, Prividentsev AI, Goriunov SV, Zhilina SV, Vasin VI. [Vasin new fluoroquinolones in treatment of patients with infectious lesions in diabetic foot syndrome]. Khirurgiia 2014;10:102-8. [PUBMED: 25484159]
64. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Journal Diabetes Research and Clinical Practice 2008;80:344-51.
65. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents Chemotherapy 2005;49:2260-6.
66. NCT01199783. Application of daptomycin in MRSA infected diabetic foot in comparison to vancomycin treatment. clinicaltrials.gov/show/NCT01199783 (accessed September 2014) 29 April 2010.
67. NCT01370616. A phase III., randomized, double-blind, active comparator-controlled clinical trial to study the efficacy and safety of ertapenem sodium (MK-0826) versus piperacillin/tazobactam sodium in the treatment of diabetic foot infections in Chinese adults. clinicaltrials.gov/show/NCT01370616 (accessed September 2014) 2011.
68. Bader MS. Diabetic foot infection. American Family Physician 2008;78(1):71-9.
69. Berendt AR, Peters EJ, Bakker K, Embil JM, Eneroth M, Hinchliffe RJ, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes/Metabolism Research and Reviews 2008;24 Suppl 1:145-61.
70. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database of Systematic Reviews 2013; Vol. 10.1002/14651858.ED000075.
71. Blanes JI, Representatives of Spanish Society of Surgeons (ACS), Representatives of Spanish Society of Angiology and Vascular Surgery (SEACV), Representatives of Spanish Society of Emergency Medicine (SEMES), Spanish Internal Medicine Society (SEMI), Representatives of Spanish Society of Critical Care Medicine and Coronary Units (SEMICYUC), Representatives of Spanish Society of Chemotherapy (SEQ). Consensus document on treatment of infections in diabetic foot [Documento de consenso sobre el tratamiento de las infecciones en el pie del diabectico]. Revista Española de Quimioterapia 2011;24(4):233-62.
72. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366(9498):1719-24.
73. Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic wounds. Health Technology Assessment 1999; Vol. 3, issue 17.
74. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Bowering K, Embil JM. Foot Care. Canadian Journal of Diabetes 2013;37 Suppl 1:145-9.
75. Crouzet J, Lavigne JP, Richard JL, Sotto A. Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. International Journal of Infectious Diseases 2011;15:e601-10.
76. Edmondes M. Infection in the neuroischemic foot. International Journal of Low Extremity Wounds 2005;4(3):145-53.
77. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). Journal of Foot and Ankle Surgery 2006;45 Suppl 5:1-66.
78. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58(6):579-88.
79. Higgins JPT, Thompson, SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
80. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
81. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJG, Armstrong DG, et al. Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clinical Infectious Diseases 2012;54:(12):1679-84.
82. Lipsky BA, Peters EJG, Berendt AR, Senneville E, Bakker K, Embil JM, et al. Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:234-5.
83. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26(5):1435-8.
84. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
85. Lipsky BA. Medical treatment of diabetic foot infections. Clinical Infectious Diseases 2004;39 Suppl 2:104-14.
86. Lipsky BA, Berebdt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clinical Infectious Diseases 2004;39(7):885-910.
87. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. Journal of Antimicrobial Chemotherapy 2007;60(2):370-6.
88. Lipsky BA, Hoey C, Cruciani M, Mengoli C. Topical antimicrobial agents for preventing and treating foot infections in people with diabetes (Protocol). Cochrane Database of Systematic Reviews 2014, Issue Issue 3.
89. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012;12:Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub2.
90. McKittrick LS. Recent advances in the management of gangrene and infections in patients with diabetes mellitus. Journal of Digestive Diseases 1946;13:142-8.
91. MedlinePlus. US National Library of Medicine. National Institutes of Health Page last updated on 29 January 2015; Vol. Bethesda, US:http://www.nlm.nih.gov/medlineplus/.
92. Nelson EA, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technology Assessment 2006;10(12):iii-iv, ix-x, 1-221.
93. National Institute for Health and Clinical Excellence. NICE clinical guideline 119. Diabetic foot problems. Inpatient management of diabetic foot problems. NHS March 2011.
94. World Health Organization. Antimicrobial resistance: global report on surveillance. Vol. ISBN 978 92 4 156474 8, France: World Health Organization, 2014.
95. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
96. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990;13:513-21.
97. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study [Diabetologia]. 2007 50;1:18-25.
98. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008;10:1826-34.
99. Raspovic KM, Wukick DK. Self-reported quality of life and diabetic foot infections. Journal of Foot and Ankle Surgery 2014;53(6):716-9.
100. Regan JS, Bowen BD, Fernbach PA. Reduction in mortality and loss of limbs in diabetic gangrene and infection. Archives of Surgery 1949;59(3):594-600.
101. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-62.
102. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
103. Selva A, Barajas-Nava LA, Gianneo OD, Solà I, Bonfill X, Lipsky BA. Systemic antibiotics for treating diabetic foot infections. Cochrane Database of Systematic Reviews 2011.
104. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 28 January 2011).
105. Sterne JAC. Why the Cochrane risk of bias tool should not include funding source as a standard item [editorial]. Cochrane Database of Systematic Reviews 2013; Vol. 10.1002/14651858.ED000076.
106. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:1-16.
107. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. American Journal of Health-System Pharmacy 1995;52(11):1199-207.